OnPAR-the Online Partnership to Accelerate Research-seeks to provide a second opportunity for funding of high-quality, unfunded applications originally submitted to the National Institutes of Health and other national and international funding agencies. OnPAR will match applicable, unfunded applications with the research priorities of nongovernment organizations such as private biomedical foundations, pharmaceutical companies, venture capital funds, and other private funds. Funding organization members will review and make final funding decisions through a simple, 2-step process whereby applicants can submit public abstracts directly to OnPAR. If a member requests additional information, then, by invitation only, an applicant can submit their original unfunded application and their peer review summary statement.
icantly, depending on the disease area (2) . The top NIH institutes, in terms of applications received, funded between 13% and 29.6% of applications ( Table 1) . As shown in Table 1 , the overall funding rate for National Heart, Lung, and Blood Institute was 21.9%; however, the funding rate for Research Project Grants (R01) was only 13.0% (3) . This leaves many outstanding cardiovascular research projects unfunded. These unfunded projects now have a second opportunity for funding through the Online Partnership to Accelerate Research (OnPAR), which will be described in the following text. 
HOW DOES OnPAR WORK?
OnPAR will rely on 3 pillars that support the entire research enterprise: applicants, members, and partners ( Figure 1 ).
Applicants will submit their abstracts and application material for consideration by members. Members will consider those applications for funding. Partners will inform high-scoring, unfunded applicants about
OnPAR after applications are peer-reviewed and final funding decisions are made.
APPLICANTS
Applicants represent the key to unlocking the success of the OnPAR public-private partnership. OnPAR will succeed as long as applicants submit their abstracts and application materials for review to further accelerate research discovery and development.
The benefit for applicants is simple. Researchers can spend months generating preliminary data and preparing the necessary documents (including a robust research strategy, detailed budget, and other requirements) for their proposal. Even if this proposal is well conceived, it may not be selected for funding (6) .
Application success rates vary by disease area, as stated previously, as well as by type of application ( Table 2) .
For applicants across all grant mechanisms, there is no cost to submit application materials to OnPAR.
It should take no more than 5 to 10 min to register and enter a public abstract.
The abstract submission is a simple 2-step process:
1. Registration: the applicant enters basic information to register for OnPAR access.
2. Abstract submission: the applicant submits the same "public" abstract that was submitted with the NIH application.
After the abstract is submitted, it is "matched," if applicable, with the research priority areas of OnPAR members. At their own discretion, each member may request additional information if interested in reviewing the application.
If a member requests additional information, then, by invitation only, OnPAR will ask for a:
1. Full application: this should be the exact same application that was submitted to NIH.
2. Summary statement: this is the peer review evaluation received for the application.
3. Confidentiality/nondisclosure agreement:
OnPAR will execute a confidentiality or nondisclosure agreement that will protect the applicant's intellectual property.
Applicants will know who is interested in reviewing their application. Bridge funding: if the work is an innovative or ongoing project that could benefit from a few more experiments before resubmitting to the NIH.
All members will follow their own guidelines for funding, and awards will be made through a grant or contract mechanism.
Grants are more likely if applications involve work in early discovery or translational research. Such efforts might be funded by a private foundation or charity member, although pharmaceutical companies might also provide grants. 
